Akademik Veri Yönetim Sistemi
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.31, sa.1, ss.28-35, 2021 (SCI-Expanded)
The expression of the FOXO3a gene, and its role in acute myeloid leukemia and chronic myeloid leukemia were investigated in the present study. We analyzed 101 patients diagnosed with AML, and CML, and 34 healthy individuals. The cDNAs obtained from the blood samples of patients, and healthy controls were analyzed by the Real-Time PCR using specific primers, and probes for the FOXO3a and ACTB genes. A 50-fold decrease in FOXO3a expression levels was detected in CML patients, and 8-fold decrease was detected in AML patients compared with the levels in the healthy controls. Significant difference was detected between the patients, and healthy controls (p= 0.000). However, there was no statistically significant difference between the CML and AML patient groups for FOXO3a expression level. The decrease in FOXO3a gene expression in all CML (51/51), and AML patients (50/50) was remarkable. The FOXO3a gene expression was downregulated in 91.8% (124/135) of all individuals included in the study. The present study might be an important report on emphasizing the expression profiles of FOXO3a gene in AML, and CML patents. Whether the FOXO3a gene is a valuable biomarker for early diagnosis and prognosis in CML and AML patients need to be investigated in larger study groups.